OBJECTIVE The molecular events leading to the development of GH-secreting pituitary tumours remain largely unknown. Gs α α α α ( GNAS1 ) mutations are found in 27-43% of sporadic GH-secreting adenomas in the Caucasian population, but the frequency of GNAS1 mutations in Japanese and Korean acromegalic patients was reported to be lower, 4 -9% and 16%, respectively. Other genes responsible for the tumourigenesis of GH-secreting pituitary adenomas have not been detected yet. PRKAR1A , which codes for the RI α α α α regulatory subunit of cyclic AMP-dependent protein kinase A (PKA) on 17q23-24, was recently reported to contain inactivating mutations in some Carney complex families, which involved GH-secreting adenomas in about 10%. We re-evaluated the frequency of GNAS1 mutations and investigated PRKAR1A on the hypothesis that it might play a role in the tumourigenesis of GH-secreting adenomas. DESIGN We analysed exons 8 and 9 of GNAS1 and all exons and the exon-intron boundaries of PRKAR1A with the PCR and by direct sequencing using genomic DNA extracted from 32 GH-secreting pituitary adenomas (30 GH-secreting adenomas, two GH and PRLsecreting adenomas) and 28 corresponding peripheral blood samples, and performed loss of heterozygosity (LOH) analysis of 17q23 -24 with four microsatellite markers and intragenic markers of PRKAR1A . RESULTS Seventeen of 32 (53·1%) tumours showed somatic-activating mutations of GNAS1 : 16 (53·3%) of 30 GH-secreting adenomas and one of two GH and PRL-secreting adenomas. Neither inactivating somatic mutations of PRKAR1A nor LOH of 17q23-24 were detected in any of the tumours examined. CONCLUSION We reconfirm the important role of activating mutations of GNAS1 in GH-secreting adenomas, and conclude that PRKAR1A does not play a significant role in the tumourigenesis.
Pituitary adenomas are monoclonal benign tumours that account for about 10% of all intracranial neoplasms. Little is known about the pathogenetic mechanisms driving pituitary adenomas. The most frequent alterations are oncogenic mutations of Gs α protein (Landis et al ., 1989; Lyons et al ., 1990) , which are detected in a subset of GH-secreting adenomas, and reduced expression of the tumour suppressor gene p16
INK4a due to methylation (Woloschak et al ., 1996) . In contrast, somatic mutations of the MEN1 gene are rare in pituitary adenomas (Zhuang et al ., 1997; Tanaka et al ., 1998) . Although other candidate genes for tumourigenesis of pituitary adenomas have been studied, genetic changes are infrequently found in pituitary adenomas. G proteins are transducers that link extracellular receptorbound ligands to intracellular secondary messenger systems. Adenylyl cyclase activity is under stimulatory control by Gs and inhibitory control by Gi. Activating mutations of α -subunits of Gs and Gi2 that convert these subunits into putative oncoproteins, which are termed gsp and gip , respectively, have been described (Landis et al ., 1989) . Point mutations at codon 201 (Arg → Cys or His) in exon 8 or 227 (Gln → Arg or Leu) in exon 9 in the Gs α gene ( GNAS1 ) result in the constitutive activation of adenylyl cyclase, and are frequently found in GH-secreting adenomas. In previous reports, heterozygous missense mutations of GNAS1 were present in 27-43% of sporadic GH-secreting adenomas in the Caucasian population Lyons et al ., 1990; Barlier et al ., 1998; Salvatori et al ., 2001) , but the frequency of GNAS1 mutations in Japanese and Korean acromegalic patients was reported to be lower, 4 -9% (Hosoi et al ., 1993; Yoshimoto et al ., 1993) and 16% (Kim et al ., 2001) , respectively. Based on these results, it has been suggested that activation of the cyclic AMP (cAMP) signalling pathway could act in concert with other factors to promote tumour development.
Carney complex is an autosomal dominant syndrome characterized by multiple neoplasias, including myxomas at various sites, endocrine tumours, and lentiginosis. About 10% of patients with Carney complex have a GH-secreting pituitary adenoma that results in acromegaly (Stratakis, 2001) . Genetic defects of Carney complex are mapped to chromosomal region 2p16 (Stratakis et al ., 1996) and 17q22-24 (Casey et al ., 1998) . The PRKAR1A gene encoding the R1 α regulatory subunit of cAMPdependent protein kinase A (PKA) was mapped to 17q22-24, and several mutations of the gene were detected in some kindreds of individuals with Carney complex (Casey et al ., 2000; Kirschner et al ., 2000a) . Based on these results, we hypothesized that PRKAR1A could function as a tumour suppressor gene in some sporadic GH-secreting adenomas.
In the present study, we re-evaluated the frequency of GNAS1 mutations and analysed the role of PRKAR1A by sequencing PRKAR1A and loss of heterozygosity (LOH) of 17q23-24 in the tumourigenesis of sporadic GH-secreting adenomas.
Materials and methods

Patients and DNA extraction
Tumour tissue samples were collected from 32 patients operated on at Toranomon Hospital, Tokyo. Twenty-eight blood samples were also obtained. Fully informed consent was obtained in accordance with institutional guidelines. The study was also conducted in accordance with the provisions of the Declaration of Helsinki. There were 18 males and 14 females, with a mean age of 45·0 (range 25-73) years. Tumours included 30 GH-secreting and two GH and PRL-secreting adenomas. The other clinical information is described in Table 1 . All samples were frozen at − 70 ° C, and stored for later use. Genomic DNA was extracted from frozen tissue and peripheral blood with standard Proteinase K and phenol-chloroform extraction in cases 26-32, and DNeasy Tissue Kit (Qiagen K.K., Tokyo, Japan) for tumours and Mr GenTLE TM (TaKaRa, Kusatsu, Japan) for peripheral blood in cases 1-25, according to the manufacturer's instructions.
Primer design of GNAS1 and PRKAR1A
Nucleotide sequences of exons 8 and 9 of GNAS1 were obtained from a bacterial artificial chromosome (BAC) clone RP4 -543J19 (GenBank accession number, AL109840). We designed primers for each exon and its flanking intronic regions: Exon 8:
The human PRKAR1A was composed of 11 exons, not 10 exons as reported by Solberg et al . (1997) . Nucleotide sequences of exons 3-11 of PRKAR1A were obtained from a BAC clone hRPK.62_F_10 (AC005799). In addition, nucleotide sequences of exon 2 and exons 1a (noncoding exon) and 1b (noncoding exon) were obtained from a BAC clone RP11-120M18 (AC079210) and 5 ′ flanking region of PRKAR1A (Y07641), respectively. We synthesized oligonucleotide primers for exons 3-11 and their flanking intronic regions according to the report by Casey et al . (2000) , but designed new oligonucleotide primers for exons 1a, 1b and 2: Exon 1a:
PCR and sequence analysis
Genomic DNA (100 ng) was subjected to 35 cycles of PCR in a reaction mixture containing 2 µ l of 10 × PCR buffer with 1·6 µ l of dNTP, 1·0 unit of AmpliTaq Gold (Applied Biosystems, Tokyo, Japan), 10 nmol each of a sense primer and antisense primer, and 11·3 µ l of H 2 O. Each PCR cycle contained a denaturation step at 95 ° C for 30 s, annealing step at 56 ° C for 30 s, and extension step at 72 ° C for 60 s for GNAS1 ; and a denaturation step at 94 ° C for 20 s, annealing step at 58 ° C for 30 s, and extension step at 72 ° C for 45 s for PRKAR1A , in a GeneAmp PCR system 9700 (Applied Biosystems). The PCR products were electorophoresed in an 8% polyacrylamide gel to confirm amplification. After treatment of PCR products with exonuclease I and shrimp alkaline phosphatase (Amersham Bioscience, Tokyo, Japan), samples were subjected to direct sequencing in sense and antisense directions using an ABI PRISM BigDye TM terminators v3·0 cycle sequencing kit (Applied Biosystems) and analysed on an ABI PRISM 3700 analyser (Applied Biosystems).
LOH analysis
For LOH analysis, genomic DNAs from 28 paired DNA samples of patient's peripheral blood and tumour tissues were analysed with polymorphic 17q23-24 markers: D17S942, D17S807, D17S795, and D17S789 (Dib et al ., 1996) . One of each oligonucleotide primer pair was labelled with 6-FAM fluorescent dye (Applied Biosystems). PCR, gel electrophoresis, and data analysis were performed as described (Shintani et al ., 1995) . To minimize the effects of possible contamination by DNA from normal tissue, the number of PCR cycles was either 25 or 30, but never more than this. LOH was considered present when the signal intensity of one allele was reduced by more than 50% in comparison with the corresponding allele in normal DNA. In addition, intragenic polymorphic markers of PRKAR1A were analysed at direct sequencing.
Data analysis
The Mann-Whitney rank sum test was used to test for differences of basal serum GH levels and GH levels provocated by GHreleasing hormone (GHRH) between patients with mutant and wild-type GNAS1 .
Results
Somatic mutations of GNAS1
Based on the hypothesis that inactivating mutations of PRKAR1A might occur independent of GNAS1 mutations, tumours were first screened for activating mutations of GNAS1. Because activating GNAS1 mutations are located in exon 8 or 9, we screened exons 8 and 9 of GNAS1. Seventeen of 32 (53·1%) cases showed somatic mutations of GNAS1: 16 (53·3%) of 30 GH-secreting adenomas, and one of two GH and PRL-secreting adenomas (Table 2 ). Mutations at codon 201 replaced Arg (CGT) with either Cys (TGT) in 15 cases, or His (CAT) in one case. Another mutation replaced Gln (CAG) with Arg (CGG) at codon 227. Both mutations were mutually exclusive. We also investigated GNAS1 mutations in peripheral blood DNA (15 cases out of 17), but did not detect any. Average basal serum GH levels in patients with and without GNAS1 mutations were 64·9 µg / l and 32·6 µg / l, respectively. There was not significant difference between the two groups (P = 0·1084). On GHRH provocation test, we calculated the stimulation ratio as maximum GH levels/basal GH levels. The ratios in groups with and without mutations were 173% and 544% on average, respectively. The stimulation ratios were significantly lower in patients with mutations than without (P < 0·05). 
Sequence analysis of PRKAR1A
Although we analysed the nucleotide sequence of PRKAR1A of genomic DNA from tumour tissue and peripheral blood, neither somatic nor germline mutations were detected except for two types of single nucleotide polymorphisms (SNPs) in six cases and T insertion at intronic sequences (exon 4 IVS −5) in 19 cases (Table 2 ). One of SNPs was an A to C heterozygous change in exon 1a (5′untranslated region) in four tumours and another was a G to A heterozygous change in exon 6 (cDNA position 546) in two tumours, which did not cause any change of amino acid. On database, four Ts are consecutively located from −8 to −5 at 5′intronic sequences to the start of exon 4; however, consecutive five Ts caused by a T insertion were detected in 19 cases. These 4T/5T polymorphisms were heterozygous in 17 cases, and homozygous in 15 cases. These nucleotide changes were observed in the respective leukocyte DNA. Because every nucleotide change was also detected in peripheral blood samples, the nucleotide changes suggest polymorphism. The frequency of these polymorphisms was analysed in 50 unrelated anonymous DNA samples from healthy individuals. In the A/C polymorphism on exon 1a, the frequency of A and C was 98% and 2%, respectively. In the G/A polymorphism on exon 6, the frequency of G and A was 98% and 2%, respectively. In the 4T/5T polymorphism on exon 4 IVS-5, the frequency of 4T and 5T was 71% and 29%, respectively. These polymorphisms were not reported by Kirschner et al. (2000b) .
LOH analysis
Although we analysed LOH of 17q23-24 with 4 microsatellite markers, no LOH was revealed in 28 cases (Table 2) . Because peripheral blood samples were not always available, information on LOH in four cases was not obtained. In addition, we analysed LOH with intragenic markers: exon 1a 103 A/C, exon 6 546 G/A, and T insertion at exon 4 IVS-5. Direct sequencing showed no LOH in 22 cases who showed heterozygosity in at least one of three markers (Table 2 ).
Discussion
The proliferation of pituitary somatotroph cells and secretion of GH are under dual hypothalamic regulation, stimulated by GHRH and inhibited by somatostatin. These hormones bind to specific cell surface receptors that interact with the heterotrimeric G proteins Gs (GHRH) or Gi (somatostatin) to stimulate or inhibit the production of cAMP by adenylyl cyclase, respectively. cAMP stimulates PKA, which in turn phosphorylates many proteins that can regulate gene expression, including cAMPresponsive element binding protein (CREB). Gsα, the gene for which is located on chromosome 20, is a subunit of the Gs signalling protein. The GNAS1 mutation of codon 201 (Arg → Cys or His) or 227 (Gln → Arg or Leu) produces independent activation of the adenylyl cyclase system (Landis et al., 1989; Lyons et al., 1990; Spada et al., 1993; Shimon & Melmed, 1997) . The GNAS1 mutations have been demonstrated in 27-43% of GH-secreting pituitary tumours in Caucasian patients (Barlier et al., 1998; Landis et al., 1990; Lyons et al., 1990; Salvatori et al., 2001) , 16% in Korean patients (Kim et al., 2001) , and 4 -9% in Japanese patients (Hosoi et al., 1993; Yoshimoto et al., 1993) with acromegaly. This discrepancy in the frequency of GNAS1 mutations has been thought to reflect a geographical or ethnic influence. The present study demonstrated that GNAS1 mutation was detected in 53·1% of sporadic GH-secreting adenomas and the frequency of mutations in Japanese patients was 53·3% (16 of 30 cases), because patients 9 and 18 were a Vietnamese and a Taiwanese, respectively. The frequency in this study was higher than that in other reports on Japanese patients (Hosoi et al., 1993; Yoshimoto et al., 1993) . Although we cannot provide a clear explanation on the difference in frequency, the cases examined in this study did not overlap with those in the previous study (Yoshimoto et al., 1993) . Further large-scale research seems to be necessary to re-evaluate the frequency. Landis et al. (1990) found GNAS1-activating mutations in 10 of 25 (40%) GH-secreting pituitary adenomas. They demonstrated that patients in the mutation-positive group came to surgery with smaller tumours and had lower serum GH levels. On the other hand, Barlier et al. (1998) reported that adenomas with GNAS1 mutations appeared to secrete significantly more GH than negative adenomas. Kim et al. (2001) reported that mean tumour size was significantly smaller in patients with GNAS1 mutation than without, but basal serum GH levels were not different in the two groups. In our cases, the average basal serum GH level in patients with GNAS1 mutations was about twice that in patients without mutations. In cases with Gsα mutations, basal GH levels was thought to be higher than those without mutations because the cAMP signalling pathway was continuously activated and additional GHRH stimulation might be less effective. On GHRH provocation test, the ratio in patients with mutations was significantly lower than that in patients without mutations. Recently, Yasufuku-Takano et al. (1999) reported that a heterozygous GNAS1 mutation renders ion channels of GH-secreting pituitary adenomas unresponsive to GHRH. Regarding tumour size in Hardy's classification, there was no significant difference between the two groups.
The pathogenesis of the remaining GH-secreting adenomas is unclear. Interestingly, phosphorylation of CREB is promoted not only in GH-secreting adenomas with GNAS1 mutations, but also in adenomas with wild-type GNAS1 (Bertherat et al., 1995) therefore other factors activating the cAMP signalling pathway seem to contribute to the tumourigenesis of GH-secreting adenomas.
GH-secreting pituitary adenomas are encountered in about 10% of cases of Carney complex (Stratakis, 2001) , an autosomal dominant multiple neoplasia syndrome which has been linked to loci on 2p16 (Stratakis et al., 1996) and 17q22-24 (Casey et al., 1998) . Kirschner et al. (2000a) and Casey et al. (2000) reported that PRKAR1A, which codes for the RIα regulatory subunit of PKA, is located on 17q23-24 and is found to be mutated in some Carney complex families. Each of the PRKAR1A mutations is predicted to lead to the production of truncated protein products by missense mutations, frameshifts, or splice site mutations (Casey et al., 2000; Kirschner et al., 2000a) . In a patient with Carney complex, LOH was found on 17q22-24 in a GH-secreting pituitary tumour (Kirschner et al., 2000a) . LOH in tumours suggests that PRKAR1A is a tumour suppressor gene.
Hormonally mediated increases in intracellular cAMP levels lead to the dissociation of a catalytically inactive complex of PKA (R2C2) containing a cAMP-binding regulatory subunit (R) and free (catalytic active) subunit (C); the active catalytic subunit then phosphorylates multiple target proteins including CREB. Four distinct R isoforms (RIα, RIβ, RIIα, RIIβ) showed tissuespecific expression patterns (McKnight, 1991) . Loss of the RIα subunit of PKA is expected to activate PKA and subsequent downstream signalling such as GH hypersecretion and tumourigenesis of somatotroph cells.
In the present study, we analysed the nucleotide sequence of PRKAR1A by direct sequencing of all exons and their flanking intronic sequences, and LOH on 17q23-24 with microsatellite markers and intragenic markers to investigate whether PRKAR1A mutations play a role in the tumourigenesis of sporadic GHsecreting adenomas. Neither inactivating mutations of PRKAR1A nor LOH on 17q23-24 were detected in GH-secreting adenomas. From these results, inactivation of PRKAR1A by mutations or LOH occurs infrequently if at all in sporadic GH-secreting pituitary adenomas.
Because GHRH acts by binding to the GHRH receptor, which activates adenylyl cyclase and promotes the growth and formation of somatotroph cells, Salvatori et al. (2001) and Lee et al. (2001) hypothesized that activating mutations of the GHRH receptor gene might occur in a subset of GH-secreting pituitary adenomas, and analysed 26 and 54 tumours, respectively. However, they found several SNPs and somatic mutations that did not increase intracellular cAMP. They concluded that activating mutations of the GHRH receptor gene in GH-secreting adenomas are rare or absent. Only Gsα among elements in the cAMP signalling pathway plays an important role in the tumourigenesis of GH-secreting adenomas, but other genes responsible remain to be elucidated in tumours lacking activating GNAS1 mutations.
In the present study, GNAS1 mutations were detected in 53·1% of GH-secreting pituitary adenomas; however, PRKAR1A mutations were not detected in any of the 32 cases. We reconfirm that frequent somatic mutations of GNAS1 occur in GH-secreting adenomas, and conclude that PRKAR1A does not play a significant role in the tumourigenesis of GH-secreting adenomas.
